FDA approves Vertex's first-in-class non-opioid analgesic for acute ...
1 day ago · Jacqueline Corrigan-Curay, J.D., M.D., acting director of the FDA's Center for Drug Evaluation and Research, stated that the approval of Journavx is an important public health milestone in acute ...
FDA genehmigt Vertex' neuartiges nicht-opioides Schmerzmittel …
1 day ago · Die FDA hat Journavx die Bezeichnungen Breakthrough Therapy, Fast Track und Priority Review verliehen. Die Zulassung von Journavx wurde Vertex Pharmaceuticals Incorporated erteilt.
FDA menyetujui analgesik non-opioid pertama di kelasnya dari …
Journavx tidak boleh digunakan bersama dengan penghambat CYP3A yang kuat, dan pasien disarankan untuk menghindari makanan atau minuman yang mengandung jeruk bali saat minum obat. FDA memberikan Journavx sebutan Terapi Terobosan, Jalur Cepat, dan Peninjauan Prioritas. Persetujuan Journavx diberikan kepada Vertex Pharmaceuticals Incorporated.
FDA approva il primo analgesico non oppioide di Vertex per il …
1 day ago · La FDA ha concesso a Journavx le designazioni di Terapia Innovativa, Fast Track e Revisione Prioritaria. L'approvazione di Journavx è stata concessa a Vertex Pharmaceuticals Incorporated. Questo articolo è stato generato e tradotto con il supporto dell'intelligenza artificiale e revisionato da un redattore. Per ulteriori informazioni ...
La FDA aprueba el primer analgésico no opioide de su clase de …
1 day ago · La FDA otorgó a Journavx las designaciones de Terapia Innovadora, Vía Rápida y Revisión Prioritaria. La aprobación de Journavx fue concedida a Vertex Pharmaceuticals Incorporated.
La FDA approuve le premier analgésique non opioïde de Vertex …
1 day ago · La FDA a accordé à Journavx les désignations de thérapie révolutionnaire, de procédure accélérée et d'examen prioritaire. L'approbation de Journavx a été accordée à Vertex Pharmaceuticals Incorporated. Cet article a été généré et traduit avec l'aide de l'IA et revu par un rédacteur. Pour plus d'informations, consultez nos T&C.
Vertex scores double win with non-opioid pain drug
2 days ago · Vertex Pharma says its much-anticipated non-opioid painkiller, VX-548, clears two phase 3 trials en route to an FDA filing later this year.
Undaunted Vertex closes in on FDA nod for non-opioid pain drug
Oct 28, 2024 · Fast-forward to today, and Vertex Pharmaceuticals is on the verge of gaining an FDA approval for suzetrigine (VX-548), a nonaddictive oral treatment that is on track to become the first major...
Vertex’s pain drug suzetrigine advances in FDA approval process
Apr 19, 2024 · Vertex Pharmaceuticals’ suzetrigine, previously named VX-548, is steadily advancing along its rolling submission approval pathway okayed by the US Food and Drug Administration (FDA) for moderate-to-severe acute pain.
FDA zatwierdza pierwszy w swojej klasie nieopioidowy lek …
1 day ago · FDA przyznała Journavx oznaczenia Breakthrough Therapy, Fast Track i Priority Review. Zatwierdzenie Journavx zostało przyznane firmie Vertex Pharmaceuticals Incorporated. Artykuł został przetłumaczony przy pomocy sztucznej inteligencji. Zapoznaj się z Warunkami Użytkowania, aby uzyskać więcej informacji. ...